Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (NYSE: RFL) on August 5, 2024. The report discloses changes to the Company's Board of Directors effective immediately on the date of the report.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Director Departure: Mark McCamish resigned as a director of Rafael Holdings, Inc., effective August 5, 2024.
- Director Election: Mark N. Stein, MD, was elected as a director on August 5, 2024.
- Committee Assignments: Dr. Stein was elected to the Audit, Compensation, and Corporate Governance committees.
Management Commentary and Background
Dr. Stein, age 53, brings extensive experience in medical oncology, specifically focusing on genitourinary malignancies. He serves as an Associate Professor of Medicine and Director of the Genitourinary Medical Oncology Service at Columbia University Irving Medical Center (CUIMC). His background includes leading early-stage clinical trials with novel therapeutics and working with pharmaceutical companies to advance early assets. His academic interests include the use of immunotherapy for prostate and kidney cancer.
Key Facts for Investor Verification
- Confirm the effective date of Mark McCamish's resignation and Mark N. Stein's election (August 5, 2024).
- Verify Dr. Stein's specific qualifications and experience in clinical trials relevant to the Company's pipeline.
- Check subsequent filings for any impact on Board committee quorum or voting dynamics.